Influence of protocols with Lasertherapy for the prevention of chemotherapy-induced dysgeusia in patients with breast cancer

Not Applicable

Recruiting

• Conditions: Breast malignant neoplasm; Cancer chemotherapy session; Disorders of smell and taste; D004408; D000971; D003520; D004317; D000077143; D017239

• Registration Number: RBR-9x5zrgm
• Lead Sponsor: niversidade Federal do Ceará

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-12-07
• Last Update Posted: 19 December 2023
• Study Completion: 2024-03-13

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

Patients over 18 years old; breast cancer stages II, III and IV; adjuvant, neoadjuvant or palliative; treatment with drugs Doxorubicin, Cyclophosphamide and Taxol

Exclusion Criteria

Radiotherapy to the head and neck; smokers; anemia; untreated diabetes mellitus; after COVID-19

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To evaluate the reduction and/or prevention of changes in taste through the method of applying laser therapy prior to chemotherapy with different protocols, Red (V) with 2J + Infrared (IV) 3J, Placebo V + IV application and Placebo IV + application de V. Based on the analysis using the ANOVA-RM/Bonferroni, Friedman/Dunn, chi-square/Fisher's exact tests using the SPSS 20.0 software, adopting a 95% confidence level, we identified that the incidence of Dysgeusia increased from the third QT cycle (p<0.001) and taste sensitivity events <50% were directly associated with the number of chemotherapy cycles (p<0.001), LBI protocols V(+placebo) and IV(+placebo ) (p<0.001) were inferior to the V+IV protocol in subjective (p<0.001) and objective tests (p<0.005).

Secondary Outcome Measures

Name	Time	Method
o secondary outcomes are expected.